New antifungal drug APX001 gets first human safety check
NCT ID NCT02957929
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 1 trial tested the safety and tolerability of a new antifungal drug called APX001 in 46 healthy volunteers. Researchers gave single and multiple doses, both orally and intravenously, to see how the body handles the drug and whether food affects it. The study also looked at potential interactions with other drugs. Since this is an early-stage trial, it focuses on safety and drug processing, not on treating fungal infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APX001
What this could lead to
If successful, this could pave the way for a new oral or IV treatment for serious fungal infections.
What could go wrong
This is a very early Phase 1 trial in only 46 healthy people, not patients. It only checks safety and how the drug moves through the body, not whether it actually fights infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PRA Health Sciences
Groningen, Netherlands
-
PRA Health Sciences (PRA) - Early Development Services (EDS)
Groningen, 9728 NZ, Netherlands